These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 1376598)

  • 1. The differential diagnosis of primary peritoneal papillary tumors.
    Gitsch G; Tabery U; Feigl W; Breitenecker G
    Arch Gynecol Obstet; 1992; 251(3):139-44. PubMed ID: 1376598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas.
    Ordóñez NG
    Am J Surg Pathol; 1998 Oct; 22(10):1203-14. PubMed ID: 9777982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
    Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
    Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study.
    Ordóñez NG
    Mod Pathol; 2006 Jan; 19(1):34-48. PubMed ID: 16056246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update.
    Ordóñez NG
    Adv Anat Pathol; 2006 Jan; 13(1):16-25. PubMed ID: 16462153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
    Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
    Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma.
    Chapel DB; Husain AN; Krausz T; McGregor SM
    Am J Surg Pathol; 2017 Dec; 41(12):1675-1682. PubMed ID: 28877056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative immunohistochemical study of peritoneal and ovarian serous tumors, and mesotheliomas.
    Khoury N; Raju U; Crissman JD; Zarbo RJ; Greenawald KA
    Hum Pathol; 1990 Aug; 21(8):811-9. PubMed ID: 1696923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas.
    Ordóñez NG
    Hum Pathol; 2005 Nov; 36(11):1163-7. PubMed ID: 16260268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma.
    Andrici J; Jung J; Sheen A; D'Urso L; Sioson L; Pickett J; Parkhill TR; Verdonk B; Wardell KL; Singh A; Clarkson A; Watson N; Toon CW; Gill AJ
    Hum Pathol; 2016 May; 51():9-15. PubMed ID: 27067777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful.
    Barnetson RJ; Burnett RA; Downie I; Harper CM; Roberts F
    Am J Clin Pathol; 2006 Jan; 125(1):67-76. PubMed ID: 16482993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Papillary serous carcinoma of peritoneum: case study and review of the literature on the differential diagnosis of malignant peritoneal tumors.
    Koutselini HA; Lazaris AC; Thomopoulou G; Papayannopoulou A; Kairi-Vasilatou E
    Adv Clin Path; 2001 Jul; 5(3):99-104. PubMed ID: 11753882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
    Comin CE; Saieva C; Messerini L
    Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours.
    Garcia-Prats MD; Ballestin C; Sotelo T; Lopez-Encuentra A; Mayordomo JI
    Histopathology; 1998 May; 32(5):462-72. PubMed ID: 9639123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOX6 Expression Is Sensitive for Peritoneal Epithelioid Malignant Mesothelioma, But Not Specific in the Differential Diagnosis With Tubo-ovarian Serous Neoplasia.
    Chapel DB; Hirsch MS
    Am J Surg Pathol; 2022 Feb; 46(2):213-219. PubMed ID: 34411029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
    Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
    J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions.
    Delahaye M; van der Ham F; van der Kwast TH
    Diagn Cytopathol; 1997 Aug; 17(2):115-20. PubMed ID: 9258618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary papillary serous neoplasia of the peritoneum: a clinicopathologic and ultrastructural study of eight cases.
    Raju U; Fine G; Greenawald KA; Ohorodnik JM
    Hum Pathol; 1989 May; 20(5):426-36. PubMed ID: 2707793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant peritoneal mesothelioma presented as peritoneal adenocarcinoma or primary ovarian cancer: case series and review of the clinical and immunohistochemical features.
    Taşkın S; Gümüş Y; Kiremitçi S; Kahraman K; Sertçelik A; Ortaç F
    Int J Clin Exp Pathol; 2012; 5(5):472-8. PubMed ID: 22808303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas.
    Ordóñez NG
    Mod Pathol; 2013 Apr; 26(4):553-62. PubMed ID: 23196794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.